Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2001 2
2006 3
2008 1
2010 1
2011 4
2012 3
2013 2
2015 1
2017 1
2018 4
2019 2
2020 0
Text availability
Article attribute
Article type
Publication date

Search Results

20 results
Results by year
Filters applied: . Clear all
Page 1
Identification of genetic variants associated with Huntington's disease progression: a genome-wide association study.
Moss DJH, Pardiñas AF, Langbehn D, Lo K, Leavitt BR, Roos R, Durr A, Mead S; TRACK-HD investigators; REGISTRY investigators, Holmans P, Jones L, Tabrizi SJ. Moss DJH, et al. Lancet Neurol. 2017 Sep;16(9):701-711. doi: 10.1016/S1474-4422(17)30161-8. Epub 2017 Jun 20. Lancet Neurol. 2017. PMID: 28642124 Clinical Trial.
BACKGROUND: Huntington's disease is caused by a CAG repeat expansion in the huntingtin gene, HTT. Age at onset has been used as a quantitative phenotype in genetic analysis looking for Huntington's disease modifiers, but is hard to define and not always available. . …
BACKGROUND: Huntington's disease is caused by a CAG repeat expansion in the huntingtin gene, HTT. Age at onset has been used as a qua …
International Parkinson and movement disorder society evidence-based medicine review: Update on treatments for the motor symptoms of Parkinson's disease.
Fox SH, Katzenschlager R, Lim SY, Barton B, de Bie RMA, Seppi K, Coelho M, Sampaio C; Movement Disorder Society Evidence-Based Medicine Committee. Fox SH, et al. Mov Disord. 2018 Aug;33(8):1248-1266. doi: 10.1002/mds.27372. Epub 2018 Mar 23. Mov Disord. 2018. PMID: 29570866 Review.
International Guidelines for the Treatment of Huntington's Disease.
Bachoud-Lévi AC, Ferreira J, Massart R, Youssov K, Rosser A, Busse M, Craufurd D, Reilmann R, De Michele G, Rae D, Squitieri F, Seppi K, Perrine C, Scherer-Gagou C, Audrey O, Verny C, Burgunder JM. Bachoud-Lévi AC, et al. Front Neurol. 2019 Jul 3;10:710. doi: 10.3389/fneur.2019.00710. eCollection 2019. Front Neurol. 2019. PMID: 31333565 Free PMC article.
The European Huntington's Disease Network (EHDN) commissioned an international task force to provide global evidence-based recommendations for everyday clinical practice for treatment of Huntington's disease (HD). ...
The European Huntington's Disease Network (EHDN) commissioned an international task force to provide global evidence-based recommenda …
Cannabinoids for Treatment of Dystonia in Huntington's Disease.
Saft C, von Hein SM, Lücke T, Thiels C, Peball M, Djamshidian A, Heim B, Seppi K. Saft C, et al. J Huntingtons Dis. 2018;7(2):167-173. doi: 10.3233/JHD-170283. J Huntingtons Dis. 2018. PMID: 29562549
BACKGROUND: Motor symptoms in Huntington's disease (HD) are heterogeneous with dystonia being described as a symptom with a very high prevalence not only in juvenile cases. ...METHOD: The Unified Huntington's Disease Rating Scale (UHDRS) motor score, including a cho …
BACKGROUND: Motor symptoms in Huntington's disease (HD) are heterogeneous with dystonia being described as a symptom with a very high …
Reduced Cancer Incidence in Huntington's Disease: Analysis in the Registry Study.
McNulty P, Pilcher R, Ramesh R, Necuiniate R, Hughes A, Farewell D, Holmans P, Jones L; REGISTRY Investigators of the European Huntington's Disease Network. McNulty P, et al. J Huntingtons Dis. 2018;7(3):209-222. doi: 10.3233/JHD-170263. J Huntingtons Dis. 2018. PMID: 30103338
BACKGROUND: People with Huntington's disease (HD) have been observed to have lower rates of cancers. OBJECTIVE: To investigate the relationship between age of onset of HD, CAG repeat length, and cancer diagnosis. METHODS: Data were obtained from the European Huntington
BACKGROUND: People with Huntington's disease (HD) have been observed to have lower rates of cancers. OBJECTIVE: To investigate the re …
Safety and efficacy of pridopidine in patients with Huntington's disease (PRIDE-HD): a phase 2, randomised, placebo-controlled, multicentre, dose-ranging study.
Reilmann R, McGarry A, Grachev ID, Savola JM, Borowsky B, Eyal E, Gross N, Langbehn D, Schubert R, Wickenberg AT, Papapetropoulos S, Hayden M, Squitieri F, Kieburtz K, Landwehrmeyer GB; European Huntington's Disease Network; Huntington Study Group investigators. Reilmann R, et al. Lancet Neurol. 2019 Feb;18(2):165-176. doi: 10.1016/S1474-4422(18)30391-0. Epub 2018 Dec 15. Lancet Neurol. 2019. PMID: 30563778 Clinical Trial.
BACKGROUND: Previous trials have shown that pridopidine might reduce motor impairment in patients with Huntington's disease. ...Eligible patients had clinical onset after age 18 years, 36 or more cytosine-adenine-guanine repeats in the huntingtin gene, motor symptoms (Unif …
BACKGROUND: Previous trials have shown that pridopidine might reduce motor impairment in patients with Huntington's disease. ...Eligi …
Observing Huntington's disease: the European Huntington's Disease Network's REGISTRY.
Orth M; European Huntington's Disease Network, Handley OJ, Schwenke C, Dunnett S, Wild EJ, Tabrizi SJ, Landwehrmeyer GB. Orth M, et al. J Neurol Neurosurg Psychiatry. 2011 Dec;82(12):1409-12. doi: 10.1136/jnnp.2010.209668. Epub 2010 Nov 19. J Neurol Neurosurg Psychiatry. 2011. PMID: 21097549 No abstract available.
Deep brain stimulation in Huntington's disease: A 4-year follow-up case report.
Spielberger S, Hotter A, Wolf E, Eisner W, Müller J, Poewe W, Seppi K. Spielberger S, et al. Mov Disord. 2012 May;27(6):806-7; author reply 807-8. doi: 10.1002/mds.24959. Epub 2012 Mar 26. Mov Disord. 2012. PMID: 22451258 No abstract available.
Suicidal ideation in a European Huntington's disease population.
Hubers AA, van Duijn E, Roos RA, Craufurd D, Rickards H, Bernhard Landwehrmeyer G, van der Mast RC, Giltay EJ; REGISTRY investigators of the European Huntington's Disease Network. Hubers AA, et al. J Affect Disord. 2013 Oct;151(1):248-58. doi: 10.1016/j.jad.2013.06.001. Epub 2013 Jul 20. J Affect Disord. 2013. PMID: 23876196 Free article.
METHODS: The study cohort consisted of 2106 HD mutation carriers, all participating in the REGISTRY study of the European Huntington's Disease Network. ...Participants were assessed for suicidal ideation by the behavioural subscale of the Unified Huntington's Diseas …
METHODS: The study cohort consisted of 2106 HD mutation carriers, all participating in the REGISTRY study of the European Huntington' …
Placebo effect characteristics observed in a single, international, longitudinal study in Huntington's disease.
Cubo E, González M, del Puerto I, de Yébenes JG, Arconada OF, Gabriel y Galán JM; European Huntington's Disease Initiative Study Group. Cubo E, et al. Mov Disord. 2012 Mar;27(3):439-42. doi: 10.1002/mds.24062. Epub 2011 Dec 9. Mov Disord. 2012. PMID: 22162184
Our aim was to analyze the placebo effect in Huntington's disease. METHODS: Placebo data were obtained from an international, longitudinal, placebo-controlled trial for Huntington's disease (European Huntington's Disease Initiative Study Group). One-hundred a …
Our aim was to analyze the placebo effect in Huntington's disease. METHODS: Placebo data were obtained from an international, longitu …
20 results
Jump to page
Feedback